Replay available

Litigation Capital Management (LSE:LIT) — Results for the six months ended 31 December 2025

Results for the six months ended 31 December 2025 hosted by Litigation Capital Management (LSE:LIT) on Investor Meet Company, held 2026-03-31.

Tue, March 31, 2026 at 4:00 AMendedReplay
Litigation Capital Management (LSE:LIT) — Results for the six months ended 31 December 2025
Company
Litigation Capital Management Ltd (LSE:LIT)
Date
Tue, Mar 31, 2026, 4:00 AM ET
Replay
Watch the replay on this page · 53 min
Results news release
Interim results for the HY ended 31 December 2025 · Tue, Mar 31, 2026

On 6ix: 6ix.com/event/litigation-capital-management-limited-lit-results-for-the-six-months-ended-31-december-2025

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Good morning, ladies and gentlemen, and welcome to the LITIGATION CAPITAL MANAGEMENT LIMITED RESULTS PRESENTATION. Throughout today's recorded meeting, attendees will be in listen only mode. Questions are encouraged. They can be submitted at any time using the q and a tab situated on the right hand corner of your screen. Just type your question and press send. Before we begin, we'd like to submit the following poll, and I'm sure the company will be most grateful for your participation. I now like to hand over to the management team. David, Patrick, good morning to you both.

0:27 Good morning, everybody, and good evening to those who are joining in Australia. Patrick Maloney is my name. Most of you will know me as the CEO, and I'm joined by David Collins, the CFO. I will deal with the first part of our presentation as to where we're up to, and David will present with respect to financials. But investors will will probably observe that this will be a slightly shorter presentation than we're used to giving. That is principally because of the position the company is in currently. We are very much focused upon management of the existing portfolio, and we are not taking on any new investments at this time.

1:12 And I wanna start with performance. And what we're really seeing flowing through the financials of LCM now is the result of two large losses, two large losses at trial which have occurred, you know, pre in previous financial periods but are really being taken up in the financial accounts now, which David Wolf will talk to, but have really sort of impacted pretty significantly upon net assets. And those two large and rather concentrated investments which we're unsuccessful on have really driven that outcome in this financial period.

1:55 And and that's really detracted from what we look at with LCM on a longer term basis, which is historically a very high and performance in terms of win loss ratio and the underlying financial metrics which came with that. And I'll talk a little bit about, you know, what maybe has interrupted that otherwise really strong performance. And it's not really just LCM who's suffering in this market as well. I I mean, I don't want to detract from presenting LCM's position here, but this is really a symptom that that is, you know, flowing right across the whole sector at present. You'll see we'll see one of our listed peers presently is suffering from a a really concentrated position that it had invested in, which has recently been overturned on appeal. And if I look at some of the non listed peers that we have, you know, in all the markets in which we operate, including The UK and Asia and into The United Kingdom, we are seeing quite a bit of contraction in this industry.

3:09 And, you know, largely, that is a symptom of what LCM is really dealing with now. I wanna now turn to, you know, the proactive actions that we have taken as management. As investors will know, we launched a strategic review in September of last year. That strategic review continues. The strategic review has identified a couple of opportunities which we are currently working through. We are not at liberty due to confidentiality obligations really to go and delve into the detail of those opportunities, But there are two, at least two, real and tangible opportunities which we are working on together with our secured credit provider.

3:59 In addition to that, we have secured covenant waivers, and those covenant waivers have allowed us to continue to operate, to continue to manage, and to continue to invest into the portfolios of investments that that we currently manage. So not only have we secured covenant waivers, but we've secured an extension on our existing capital facility so that we can do that.

4:25 For my part, I've returned to a very hands on position now in terms of case management. I'm working closely with our investment managers in respect of each and every investment that we have as part of our portfolio. And as a consequence of that, we've had to make some fairly tough investment decisions, and we've had to rewrite the entire portfolio in terms of risk and in terms of prospects of success. And in respect to undertaking that exercise, we have had to elect to not pursue certain investments, and we are working our way out of certain other of those investments. So there's very much a rebalancing exercise going on. Now that is not something that can be achieved quickly.

5:11 It's something that is achieved over a period of time, and we've seen some of the consequences in relation to that. One of those is the Gladstone class action, which we had discontinued our funding in some time ago now, but that is now hitting our balance sheet, and David will talk more about that. In addition to that, we've reduced our operating cost by about 50% so far, and we are really focused upon our our core team of investment managers. And those that core team of best managers was really responsible for our historic track record and performance. In terms of progress to date of that strategic review, it might seem to investors from the outside that not a lot is happening in respect of that.

6:05 There is an enormous amount of work going on behind the scenes, an enormous amount of activity and cooperation between ourselves, our capital provider in respect of endeavoring to strike a balance between the interests of parties including equity where we can seek to recapitalize LCM. And if not, we move into a process of runoff. And that that process is taking more time than what we would like, but it is necessary. And, you know, we are pretty hopeful that that is gonna bring about a successful outcome whereby we inject additional capital into LCM, and we're able to start to rebuild LCM's balance sheet and its portfolio more widely.

6:56 So when we talk about that strategic review process, it's at a an advanced stage. We hope to be able to engage more fully with the interested parties and be in a position where we can report back, you know, hopefully, earlier than the end of the next quarter, but certainly by the end of the next quarter. And there's constructive dialogue and there's a significant degree of cooperation occurring between executives and the management team and our lenders throughout this process. I've got to say that, you know, there's a range of outcomes that could eventuate in respect of this, and we are, you know, we are relying upon debt covenant waivers and a continuation of the debt facility, and that is something that represents some risk.

7:51 So far, we've been working very cooperatively, and there's no indication whatsoever at this stage that capital will still not be forthcoming and debt covenant waivers will not be forthcoming, but it does represent risk. In the abs absence of being able to negotiate a a outcome with the introduction of capital that is satisfactory not only to the board, taking into account interest of equity participants, but also our lender, we will have to consider and probably move to a lean runoff model in respect of the existing portfolio. So all of those options that we're looking at are not without risk, but I I can say from from my perspective and from the executive's perspective that we are pretty positive about what the opportunities are.

8:46 We're now gonna move to financials. And then beyond financials, we wanna move as quickly as we can probably to q and a, and I'll hand over it now to David. Good morning, everyone. So I'm gonna start on slide seven, which just gives a summary of the investment activity in the period, and then that then filters through to the p and l balance sheet and cash flow. So, I mean, as Patrick set out, the the second half of the twenty twenty two zero five calendar year, which is our the first half of our financial year, was a very challenging period for LCM. On the left hand side, you can see we had four investments conclude in the period. There's one small win and then three losses. Additionally to that, we had an adverse cost order on the Queensland electricity claim that exceeded the level of ATE insurance protection that was in place. We announced that on the December 24.

9:43 Furthermore, we had two other losses in the period, both of which are undergoing appeal. And then post period end, we've had one small win and two small losses as well. So it's been a very challenging period for LCM. This in this period, we're focusing on the second half of of last calendar year, which is the first half of our financial year. But really the 2025 calendar year in total was was a very challenging period. On the right hand side, can see the position of the book now in terms of ongoing investments. So 46 ongoing investments as at 12/31/2025. If we move now to the, p and l on slide eight, rather than talk through sort of line by line, if we just think at a high level. So if you look about halfway down the p and l, you see the total income or total loss for this period which was minus a 106,000,000.

10:44 As Patrick mentioned, that was driven really by two large losses. They were announced, I think, on the September 15 and the first of October last year, and then also the adverse cost,

11:01 loss which we announced on the December 24. So of that a 106, I think about 87 or 88,000,000 of that is coming from those three cases. We then had a number of small smaller losses as well. And then the only other item that I would draw to your attention on on on this on the p and l above the total income result is the second line, so concluded investments performance fees on third party capital. You'll see that number is negative 6,600,000 in the period. That is the performance fees that we had accrued for on the large Polish case where we were anticipating earning performance fees on the fund one capital that had been invested into that case.

11:48 In light of the the losses that we've ex that we've suffered and the sort of deterioration in the performance of fund one, we've reversed the performance fees that were previously recognized. So now we we do not anticipate earning performance fees on that investment, but we still anticipate, LCM receiving its 25% share which can be, you know, a material still a very material amount. As we go down the p and l, so operating expenses you'll see have reduced significantly 6,100,000 in the period. As you recall, so the operating expense run rate that LCM was on sort of prior to getting into this period of difficulty was around 20,000,000 Australian dollars per annum.

12:33 And the actions that we took which Patrick alluded to in terms of reducing opex brought that down to an annualized run rate of 10,000,000 per annum. And if I break out the operating expenses, the underlying expenses there are around 5,000,000 for the first half, so in line with that 10,000,000 prior guidance. But we have had some exceptionals of 1,100,000 in the period. About half of that relates to essentially the redundancies that we implemented, in the summer of last year and most of that was simply paying people's notice periods.

13:11 And then we've also incurred a little over 300,000 Australian dollars and that's the adviser fees on the strategic review that we're running. So the underlying

13:24 opex rate, you know, on an annualized basis is around 10,000,000 Australian dollars. And as again as Patrick mentioned, the backup plan if the strategic review does not produce a deal is that we will go into a runoff model and reduce the operating expenses further. And if that is implemented, we think the annual opex rate will come down to 5,000,000. So effectively a quarter of what the company was operating at, call it eighteen eighteen to twenty four months ago. So, yeah, looking down the p and l, very challenging period and that's produced a large net loss in the period of a 108,000,000 Australian dollars. If I move now to the balance sheet, so you can see the impact of that loss on net assets.

14:14 And, obviously, this is what's driven the very meaningful drop in the share price, so net assets have fallen to around 6,000,000 Australian dollars in the period. At the bottom of that of this slide, you can see the fair value multiple of invested capital, which is now not point seven times the cash invested.

14:35 I think that the impact on net assets for LCM has been somewhat exaggerated by our move to fair value accounting. So when I joined the company about eighteen to twenty four months ago, the fair value MOIC of the assets at that point in time was around 2.5 times cash investors. Now what we've experienced since is a lot of losses and as you know we now value cases that have lost and are under appeal at around 50% of cash investors

15:06 and therefore the quantum of capital invested into cases that are now under appeal is the reason why the fair value MOIC across the book is naught point seven x. In general, you know, we've evolved our fair value accounting approach where now the approach is essentially that we don't recognize fair value uplift on cases prior to judgment. If you think about it, fair value accounting is trying to approximate the market value and while the secondary market for selling litigation funding assets is relatively thin, there isn't really much evidence out there that you can sell cases prior to trial at a premium to cash invested. And so we've sort of evolved our fair value accounting approach and now we've got a, you know, a significant quantum of capital that are cases that are under appeal and some of those are held at around 50% of cost. And then other pre judgment cases, the general rule is that they will not be marked up until you've got a positive outcome in the case. And so that's the reason why the fair value multiple of invested capital has came down quite significantly, over over the, let's say, last eighteen months.

16:22 If I move now to the cash flow statement. So the last twelve months for LCM have been really challenging. Right? So there's been a lot of cases that we were sort of hopeful and and positive on that have lost. And as a consequence of that, we haven't had much cash coming into the business. So you can see in the first half of our current financial year that we had cash generated from concluded investments of 1,400,000 Australian dollars. That's that small single win I mentioned earlier on.

16:56 If you actually look over the calendar year, the twelve months to December 31, the cash generated from concluded investments was only 5,000,000 Australian dollars over that entire period. And so that lack of cash coming into business, while there's still a lot of cash going out into funding the existing investments, is the reason why the net debt of the company has grown so rapidly. So you can see the net debt position is now

17:24 92,400,000 Australian dollars and if I was to give you that position as at today, March 31, it's increased further to a 123,000,000 Australian dollars And the, you know, the balance sheet challenges that we are in simply reflect the equity and the debt position. Right? So net assets is down to around 6,000,000 Australian dollars while the net debt is now circa a 120,000,000. And so that's what we are trying to solve for via the strategic review.

17:57 My last slide is the just to give you it's a slide I showed I think six months ago and maybe even twelve months ago to give you a view of the concentration risk that, sits within our balance sheet. So this has been our main problem, large cases where a lot of capital was deployed that have unfortunately subsequently lost. So this shows you the 10 the top 10 largest concentrations. And just so that you understand the two columns on the right, so the global capital invested, that is the sum of total capital invested being LCM shareholder capital, which is actually shown in the right hand column, plus external fund capital where that's relevant. So GAR one and GAR two are our two funds.

18:44 And so when those, funds are co investing alongside our balance sheet,

18:49 then the global capital invested will be greater than the than the shareholder capital investors. For this audience, our shareholders, it's the right hand column which is is of most interest because that identifies the shareholder capital invested into cases. And you can see that most of the large cases we've now sort of had a result on and several of them are under appealed. You can see after after sort of number four, there's you know, there's a real drop off of concentration risk for shareholders. So a lot of the challenges are somewhat behind us. I would say that the top three cases are all under appeal and so there is still some value within our balance sheet attributed to those cases. It's around 30,000,000 Australian dollars.

19:37 But hopefully, most of those large lumps are now sort of in the rearview mirror, if that makes sense. With that, I'll hand back to Patrick for the outlook. So if we look now at, you know, what management is focused on looking forward, it's really proactively looking at what happened in the last twelve months and making sure that we, you know, manage going forward to avoid the concentration risk that has perpetuated previously. We have increased the vigor with which we are managing these investments, and most of that is really done on a hands on basis by me supervising that very closely.

20:25 We have continued to secure the support from our lender. And if we just think about, you know, what that relationship is, the lender's collateral in respect of this is the portfolio which we are managing. So we really are sort of both looking at the same outcome here, which is continuing to manage these investments closely, continuing to fund these investments closely through to a successful outcome. And then finally, you know, we're very focused in respect of bringing the strategic review to a conclusion. There is meaningful interest in a capital transaction that could change the way the company looks and the the way that the company operates through the injection of additional capital.

21:13 And we are working sort of very closely with all interested parties to achieve that outcome.

21:20 And I think from there, what we'll do is we will sort of move on to questions which might which which investors might have, and that might be the best way to to sort of work through specific issues that we might need to discuss. That's great, Patrick. David, thank you very much indeed for updating Investor Relations. And please do continue to submit your questions just using the q and a tab on the right hand corner of the screen. Just while Patrick and David take a couple of moments just to review your questions, I'd just like to remind you, a recording will be available post today's call. David, as you can see, you've had a number of questions from investors both ahead of today's event and during the presentation. Thank you to everybody for your engagement. If I may just hand back to you, David, and we'll pick up from you. And then if you could ask you to read the questions, that'd be great. Yeah. So we've got a number of pre submitted questions which we will start with. So so the first two are from sort of long term shareholders, but basically saying what sort of gone wrong over the last twelve months with cases losing and a drop off versus the historic win rate. Patrick, I don't know if you want to respond to those.

22:25 Yes. So look, I think it's, you know, really we had the outcome of a number of investments which were unsuccessful over the last twelve month period. But really that is a reflection of investing in concentrated investments, you know, which were invested in many, many years before that. So I think it's probably not the right thing to say, you know, what has happened in the last twelve months. These you know, the to use an expression, the dye was in the water for a long time in respect of these investments.

22:56 Some of those, we had to make a tough decision in relation to such as the Gladstone class action. But, you know, we're genuinely sort of working very hard now and very focused upon the management of the existing portfolio through the conclusion. And, you know, I think that's the way that we look at the last twelve month period. The next question is, is there a backup plan in case Northleaf withdraws support?

23:23 So what I'd say on that is Northleaf to date have continued to provide us funding, they've provided us with covenant waivers and it's really not in their interest at all to withdraw support. Right? They're they're interested in recovering the value of their debt. So, to date they've behaved in the way that we would expect. They've continued to provide funding. In terms of backup plan, you know, if the strategic review does not produce new capital then the plan is to, as we described earlier, move into a what we call a lean runoff model where we will take the operating expenses down by another 50%. So the the annual burn rate on opex will be around 5,000,000 Australian dollars.

24:10 Again, in that scenario we would can't speak for Northleaf, we believe they would continue to provide funding to allow the cases to run off through to conclusion. The only point that we would need to reiterate is in that scenario we would obviously still be reliant on securing future debt covenant waivers, from Northleaf. So that that's important to remember. But that would be, you know, that's our current position in terms of the backup plan.

24:38 The next question is what's what is the value added stemming from the assistance of LUMINIS partners and what are the costs associated with their services? Patrick, maybe you can take the the value added. And then just on the costs, I think I mentioned in the slides earlier on that that to I think to date or in the period we paid 300,000 Australian dollars and that's that's essentially their fees for managing the strategic review. Sorry, Patrick. Yes. I I think there's two two issues there in relation to LIMITIS Partners. The first one is, you know, LIMITIS Partners have identified two prospective capital partners here who we are engaged with and who, you know, our lender is engaged with currently.

25:25 So it's really about just moving that forward to consummate if we can a transaction which which will be for the advantage of all stakeholders. In relation to any retainer, we are not paying Luminous Partners or retainer in respective of this. We did in the early stages of this. So it's really just a success fee which is determinative of a transaction occurring.

25:51 Yep. The the next question is what was the rationale for introducing fair value accounting? And, basically, it sort of identifies the challenges of using that accounting approach to reflect economic reality. So I think look, the industry has moved to fair value accounting and the difficulty that you need to sort of remember though is the nature of our investments. So they are binary investments which means they can either produce a zero or a very big number. I mean LCM has made north of eight times capital on some of its capital invested on some of its historic investments. So it can produce a very wide range of outcomes. And the difficulty with any set of financial statements for a litigation funder is that for each investment, you you have to put a single value on that asset at the balance sheet date.

26:49 And I think the challenges that that come from that is what we've experienced in the last twelve months where you you put what you believe may be a conservative value on the investment and certainly much lower than the potential win if the case is successful. But nonetheless, if you have a bad outcome, you have to write that that investment, off entirely. So you know, in my view the the use of fair value accounting in the sector is going to be this continuous evolution and you know honing the model over time. As I say, probably one of the big learnings for us over the last twelve months or so is really thinking about cases that are pre judgment or pre trial, you know, should you really be marking those up really at all? I don't think there's much evidence in the secondary markets of cases being sold at a premium, to cash investors. There's one transaction that I can I can recall where a book of cases were sold at a premium, but there was a back end guarantee associated with that deal and therefore the upfront price is in my opinion somewhat artificial?

27:58 So we have sort of learned and and evolved the model but, you know, and I think with fair value accounting it's going to be something continuous. But the the main challenge just comes back to in this sector, particularly single case funding, you know, the the the range of outcomes is so wide and yet at each balance sheet date we're required to put a singular a singular value on on each investment. And I think in other sectors you prob where fair value accounting is used, you probably don't get anything like that range of range of outcomes and therefore the impact of fair value accounting can look more pronounced for a litigation funder if you have a bad run of case outcomes. The next question is do investment managers have personal stakes in the company? How high are those relative to their salaries?

28:52 I mean, as you know, I think Patrick has around a 10% shareholding in the company. The chairman of the company has a 5% shareholding which, you know, he's acquired with his own money in the market. So there was strong alignment and then there are some of the longer serving staff also have, you know, shareholdings that are meaningful relative to their salaries. So there has been a lot of sort of staff buy into LCM and, you know, therefore staff also participating in the difficulties that shareholders have faced over the last twelve months. The next one is I'll give this for you, Patrick. So the question is, given the company is trading at a low valuation, can the board give shareholders comfort that the transaction capital raise or sale of the business will be conducted on terms that reflect the economic value of the litigation portfolio and that minority shareholders will be treated fairly?

29:52 Look. There's no doubt that we, as a board at LCM, are highly focused upon all of the stakeholders involved in the company, and that includes equity participants. When we start talking about valuation, this really sort of swings right back into what David was saying about ascribing a fair value to the book, and that's really what we're talking about here is what is the true value of the underlying portfolio here. That is a very, very difficult thing to put one's finger on. Now if you look at some of the transactions which are listed there and rolled up into that question, you know, would a capital raise be done at a value? I mean, a capital raise would now be done at what I think shareholders would perceive to be an undervalue of the book. But the reality is is that the shares are trading on the public market and, you know, shareholders are making a decision about what they regard as being the value of this company.

30:48 So, you know, what I what assurance I can give is the board is highly focused upon making sure that equity participants and, you know, a larger part of the board are equity holders as well. I will be treated fairly. The next one is, can you confirm LCM still writing more cases such as Cadence Minerals? True. We we we are not entering into any new financial commitments at present. So if we look at Cadence, Cadence was an investment that we entered into and signed a funding agreement more than twelve months ago, and we just issued a funding confirmation notice in respect of that investment. So it's a fund two investment, and it was entered into quite some time ago.

31:37 Yeah. And so on slide seven where we said there's 46 ongoing investments as of 12/31/2025, Cadence is in is in there. It was sort of undergoing due diligence sort of at that period of time. Next question is with the sort of utilization of the credit facility, how long can LCM keep meeting its ongoing financial commitments? So that's back to really what we were saying earlier on. So our lender Northleaf has behaved very very professionally, with us during this challenging period. We announced that we upsized the facility from 75,000,000 US dollars to a 100,000,000 US dollars, and they've also provided covenant waivers. Again, it's not in their interest to sort of stop.

32:31 They're interested in preserving the value of their debt and so while we can't speak for them, certainly my expectation is that the funding as it's required will continue to be provided. So so we don't foresee any sort of hard stop. The only qualification I can put to that is that that's not within our control. That is entirely their decision, but it's not in their interest to stop funding. The next case is during the recent earnings call you mentioned the case that was lost on the 10/01/2025, the so called Doyce case. Can you tell us more about it? How do you evaluate the probability to overturn it historically? Such appeals, were not largely successful.

33:20 So what I'd say on that, so yes, we announced that on the October 1. We are it probably doesn't make sense for us to publicly talk about our strategy in terms of, pursuing that appeal, but we are following the procedures and seeking permission to appeal on that case and therefore rather than talk about it publicly that's probably the most that we can say. Regarding the losses under appeal, how are you feeling about the prospects for those appeals? Patrick? Look, I think we've a couple of years now.

34:06 Sorry, David. There is a little bit of lag on Patrick's line. Just bear with us one second. Yep. Patrick, can you hear us there? I can. Yeah. Okay. We're just getting a dip in your connection coming through. Just bear with us for two seconds. I'm just going to bring you back in. Thank you. Ladies and gentlemen, just bear with us for just two seconds. Thank you very much indeed. Thank you, Patrick. I'll just request control there, and I'll just bring you back through. Okay. Can you hear can you hear us there, Patrick?

34:53 I certainly can hear you. Yeah. Thank you. Carry on, sir. Thank you. I don't know if you wanna just repeat that question there, David. Thank you. Yeah. Yes. So so there was a question question around appeals and and how we're feeling about those appeals. Look. All appeals have their difficulties associated with them. It's always you're in a much better position if you can be successful at first instance. All that said, you know, we recently concluded the the appeal hearing in respect of one of those appeals very recently, and we felt pretty good about the way that that was received by the court. So, you know, it's not particularly helpful for me to make to make predictions about what they'll be just based upon feedback from the bench and the judges that heard that appeal, but we're still feeling pretty good about that.

35:46 Then the next case question is looking at some of your larger case wins like GreenX or the two arbitration wins, have there been any recent developments? Patrick? I think I think I'm really looking at GreenX. I think the last development that we had was our success. Is that is that dropped out again? We are just yeah. You've you've just got I'm just keep your camera down, Patrick. Do bear with us thirty seconds, and we'll just bring you back in. Thank you, Patrick. I'll just request control one more time, and then, I might just keep your camera off for the purposes of, the q and a.

36:41 Thank you. Hi, Patrick. Can you hear us? I'm just gonna keep your camera off for the time being, but can you hear us okay? I'm just gonna take your camera, David, down as well just for uniformity. Just bear with me one second. Patrick, can you hear us in the room? Can you hear us there, Patrick? Do do you want me to take the question? Yeah. Please. If you could just in the meantime, and I'll try and bring Patrick, through. Thank you.

37:30 Yeah. So there's a a question on GreenX in terms of, you know, update on recent developments. So I think we put out an announcement fairly recently. I can't remember the exact date on so on the GreenX case, as many of you will recall, we have two, two awards. One is under the energy charter treaty and one is under the Australia Poland bilateral investment treaty. That's important because to avoid payment, Poland needs to defeat the two awards via the set aside proceedings, which is a bit like an appeal, but typically set asides have a very low success rate. So the the ECT award set aside took place, I think it was September of last year in Singapore.

38:20 The the judgment, if you like, has been handed down on that, and we were successful or our plaintiff was our client was successful in that instance. They are seeking so Poland is seeking to appeal that decision. That will be the last stage of that procedure, and I I think our expectation is that that will conclude probably around q And, again, we're very confident that that will that will resolve favorably. And then there is also a set aside procedure for the Australia Poland bilateral investment treaty award, which I understand is taking place in London in October. Again, you know, on our side, we are very confident that that will resolve in our favor.

39:08 So we have had positive developments there on that. Patrick, are you back? I can hear you. I've got my screen looks different, but if you can hear me, that's fine. Yeah. Did you I've taken the cameras off there, Patrick. So so we can hear you now, so please go ahead. Thank you. Yeah. Did you wanna add anything to that, Patrick, on GreenX? Not really. I I I think you summed it up there. Look. We've got a very strong judgment in respect to the set aside at first instance in Singapore. We would be confident that that will be upheld when that is appealed. We expect that that second appeal will be heard and probably the judgment delivered at or about the same time as the set aside application will be heard for the first time in the London courts.

40:01 And at that stage, we'll be in a position where we can start to reinforce at least that side of the judgment, and hopefully, that will bring about a resolution. Okay. The next question is do you expect the case one on the March 10 to be accretive to your historic MOIC, Patrick? Look. I think if you if you look at our running MOIC, there is a slide in respect of this. I think we we are running now at about a 1.7 times MOIC over the last fifteen years. And if you look at if you guess you you go back about sort of twelve to eighteen months, we were running a a MOIC of about 2.4, 2.3, 2.4.

40:56 So you can see that, you know, that's really a reflection of the losses that we've sustained in the last sort of twelve months or so. And if you think about, you know, David's comments earlier in relation to fair value accounting and the the the the current fair value uplift is point seven. That kind of coincides, you know, with our, you know, our running track record over the last fifteen years. So the next question is, have you been required to present your grounds for appeal, on the cases that have lost to Northleaf? Does their leniency reflect their confidence in committing further money to those appeals? So obviously the discussions that we have with Northleaf, it's not just the cases that are under appeal. You know, we're in discussions with them around the entire book and we have their support.

41:49 So there's nothing in terms of those specific cases that is, you know, that is going to influence North East behavior. We expect them to continue providing funding, to all of the cases in the book. Will shareholders be able to participate in any capital raise? I would just say let's see where we get to. So the the strategic review has been running, you know, since I think September 15. We're our results today, March 31. I think that's the last day as an aim listed business that we could publish our financial statements for the period. We were hoping we pushed it so late because we were hoping to be able to give you a meaningful update on the progress of the strategic review.

42:39 I think in Patrick's slides he said that we hope to be able to give you a further update in the second quarter and at that point in time, we'll be able to set out more detail on whether or not there is an equity raise and and shareholders' ability to participate in that. But again, as Patrick reiterated earlier, we are interested and focused as a board on trying to protect minority shareholders interests. We just need to keep qualifying that statement with we aren't entirely in control of the ball because of the situation with our lender and our reliance on them to continue providing debt covenant waivers. Let's see, some of these questions are similar to what we've had before.

43:43 There's a lot of hypothetical questions around an equity raise which I think I would just refer you to my prior answer. Has LCM now fully concluded the re underwrite of its existing case portfolio or or is more work being done to reevaluate the prospects of its current cases? Patrick, do you wanna respond to that one? Yeah. So so there's no there's no question that we have undertaken a full reunderwriting of the entire portfolio, but I need to I need to stress that that is an ongoing process. So we do that on a quarterly basis. So we look and we look at developments and we continue to underwrite the risk associated with these investments. The second thing I would add to that is in circumstances where, you know, you you change your view about prospects when you're underwriting reunderwriting the risk associated with these, it doesn't mean that the only option you've got available to you is to seize funding and therefore crystallize a balance sheet loss in respect of that investment.

44:47 It's often the case that we will start to negotiate our way out of those. So in respect of some of those investments where we don't have sufficient commitment to, you know, want to invest the full length right through to a contested hearing, we have engaged in a process of of trying to manage our way out of that through a negotiated outcome. The next question says, in my view, one of the biggest problems of LCM is limited disclosure, especially on the expected pipeline of future verdicts. Are you planning to change anything in your communication in that regard? So what I would say in terms of future verdict is we've gone through a period where a lot of capital invested has concluded and you know unfortunately a lot of that capital has lost.

45:39 If I look at the rest of the book now, the rest of the book is relatively young so I don't expect certainly over the course of this calendar year for there to be the level of conclusions that were that will be anything like what we experienced in the 2025 calendar year. That's probably the first point and then the second point I would say is one of the things that's really hard in this sector is predicting duration because the legal process is always, would say, always delays. You always start out these investments and the lawyers tell you two to three, you know, two to three years and it will all be done, we'll be in a trial in eighteen to eighteen to twenty four months And that just never happens. The know, the cases are always delayed, you always get trials being pushed back etcetera and duration is a common problem, for funders to to manage and therefore it's very difficult for us to say to you exactly this is what's going to conclude in the period. I mean we revisit our financial assumptions every six months and it's a continual process of the investment managers telling us oh that one's been delayed by another six months, that one's been delayed by another twelve months. So it's just it's a common issue in the the litigation sector, and therefore, it is very difficult for us to give you, you know, an accurate sort of timeline in terms of expectation of investments maturing.

47:04 I'll just add to that. If we were to to give estimates, they would be persistently wrong because, you know, we we are trying to predict one of two outcomes here, either a negotiated outcome between two commercial parties over which we don't have control. Alternatively, we're trying to predict the, you know, the period in which a judgment will be delivered on the assumption that that judgment is successful. Now judges can take anywhere from three months to two years to deliver a judgment in respect of that, and we would get two days notice or maybe only a day's notice in respect to that. So if you look at our listed peers, none of our listed peers make forecasts in respect of individual investments for single case investments.

47:52 And for the reasons we just described, it's very difficult, if not impossible, for us to do that in any sort of meaningful way. Then I think the last there's some questions that are probably not appropriate for us to comment on. There's probably the last question is how have discussions been with investors in fund one and fund two, and what's the hurdle rate before performance fees become payable again? Patrick, do you wanna pick up on the discussions and then I I can pick up on the sort of hurdle rate point? Yeah. So so the way we are in constant dialogue with the LPs who are investing in the funds, you know, they have probably not been as impacted in the same way as equity investors because of concentration.

48:43 You know, that said, I think that our LP investors are pretty anxious in the same way that that that we are to, you know, try and negotiate a situation where, you know, fresh capital could be injected into this business such that we, you know, have the confidence that we can say with conviction that we will be able to meet our co funding commitment with them. So, you know, I I think that they're very supportive of us, but at the same time, you know, like equity investors would, you know, like to see more progress in respect of the process that we're undertaking, the strategic review. But we are really you know, we're pushing that as hard as we can. And then just on the performance fees, so to date, LCM has received 29,000,000 US dollars of performance fees from fund one.

49:34 We have disclosed as a contingent liability that there is a clawback on those performance fees, and therefore, we've disclosed the contingent liability of potentially, call it 12 to 17,000,000 US dollars repayable of those performance fees. That will depend on how the remainder of the cases in fund one play out. So I would say so for fund one, I would certainly wouldn't expect more performance fees from here. And then for fund two, it's still relatively early days in in fund two. So we haven't received any performance fees to date or booked anything and it will depend on how the cases in the book play out in terms of the potential performance fees. But just as a reminder, so the performance fees that we earn so LCM doesn't receive a management fee from the funds.

50:25 It receives a 25 per four 25% performance fee on the third party profits if you like, on on fund asset profits and that's up to a 20% IRR for the fund asset investor fund investors. And then above a 20% IRR, it's potentially a 35% performance fee. So so that's the mechanism in terms of how it works. But for fund two, it's still relatively early days. Thanks. That's great. David, Patrick, thank you very much indeed. And as we come up to the hour, thank you once again to everybody for your engagement as well this morning. David, Patrick, I'll shortly redirect to redirect investors on the call to provide you with their thoughts, their expectations, and give you their feedback.

51:10 But before doing so, I just wondered, Patrick, if I may just come back to you for a couple of closing comments. Yeah. Look. I think, you know, we are grateful to be through 2025 as a calendar year. It's been a very difficult year for LCM and LCM's performance. We, you know, as a company and as a board, are very focused upon bringing the strategic review to a conclusion. We feel optimistic about that. There is real opportunity there to really recapitalize LCM and allow it to go forward for the benefit of all shareholders. And, you know, we are as impatient as you are about that process, but, you know, we are seeing some tangible steps forward in respect of that.

51:57 And I just finally say, we are not reticent to update the market. We're just constrained by confidentiality obligations whilst that process is on foot. So it's been pretty difficult for us to actually update equity investors. As soon as we're in a position to do so, we will. That's great, David Patrick. Thank you once again for updating investors. If I could please ask investors not to close the sessions, we'll now redirect you for your feedback. On behalf of the management team of LCM, we'd like to thank you very much indeed for attending today's presentation, and wish you all a good rest of

Follow Litigation Capital Management Ltd into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Patrick Moloney

CEO at LITIGATION CAPITAL MANAGEMENT LIMITED

David Collins

Chief Financial Officer at LITIGATION CAPITAL MANAGEMENT LIMITED

More from Litigation Capital Management Ltd